Category: Hematological Disorders

Home / Established Year

The FDA has approved zanubrutinib for the treatment of Waldenstrom’s macroglobulinemia

September 2021: For adult patients with Waldenström's macroglobulinemia, the FDA has approved zanubrutinib (Brukinsa, BeiGene) (WM).In ASPEN (NCT03053440), zanubrutinib was compared to ibrutinib in patients with MYD88 L265P mutat..

, , , ,

Beta Thalassemia and its consideration with COVID-19

July 2021: Beta-thalassemia is an inherited condition caused by mutations in a gene involved in the production of a component of haemoglobin, the protein that transports oxygen throughout the body. These mutations either prohibit ..

Leukemia treatment options

Because leukemia classification and prognosis stratification are complex, there is no one-size-fits-all treatment method, and it is necessary to combine careful classification and prognosis stratification to formulate treatment p..

Research progress in lymphoma

On June 17-20, 2015, the 13th International Lymphoma Conference was successfully held in Switzerland. 3700 representatives from 90 countries participated in the event. At the meeting, the research on lymphoma was brilliant, not o..

MD Anderson cancer center treatment story of a leukemia patient

Eddle and Pearlie Saddler, as his wife Pearlie hopes, "enjoy a regular life" in their South Carolina town. When they rested, Saddlers volunteered and participated in the service in the church. "We go there often, especially Eddi..

PD-1 inhibitor immunotherapy for B cell lymphoma

A review written by Young, MD, Anderson Cancer Center, USA explained the application of PD-1 inhibitor immunotherapy in B-cell lymphoma. (Blood. Online version on November 8, 2017. doi: 10.1182 / blood-2017-07-740993.)PD-1 immune..

Study finds new ideas for leukemia treatment

A new study from McMaster University in Canada said that it has discovered a new treatment strategy for acute myeloid leukemia. By stimulating the production of fat cells in the bone marrow and adjusting the bone marrow microenvir..

Peripheral T-cell lymphoma faces challenges

The Cleveland Clinic of the United States Eric D. His et al. Reported that the diagnosis of peripheral T cell lymphoma (PTCL) in the United States varies greatly, and often lacks important phenotypic information to fully distingui..

AstraZeneca targeted drug Acalabrutinib has a new way to treat chronic lymphocytic leukemia

Acalabrutinib is a second-generation tyrosine kinase (BTK) inhibitor, a newer drug that can improve the survival of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).The researchers believe that BTK inhibitors comb..

Pathogenesis and treatment of mature T cell tumors

Mature T-cell tumors, such as non-Hodgkin T-cell lymphoma, are highly invasive and drug-resistant, and patients often have a poor prognosis. Recently, "Nature" series of two articles published a new interpretation of the pathogene..

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy